2 days Ago By Defense World Staff
American Century Companies Inc. decreased its position in shares of MannKind Co. ( NASDAQ:MNKD – Free Report ) by 19.
8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 136,390 shares of the biopharmaceutical company’s stock after selling 33,689 shares during the period. American Century Companies Inc.
’s holdings in MannKind were worth $877,000 as of its most recent filing with the Securities and Exchange Commission. Several other large investors also recently made changes to their positions in MNKD. Jones Financial Companies Lllp grew its holdings in MannKind by 3,294.
8% during the 4th quarter. Jones Financial Companies Lllp now owns 6,586 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 6,392 shares during the period. Beirne Wealth Consulting Services LLC acquired a new position in MannKind during the fourth quarter worth $66,000.
Marshall Investment Management LLC bought a new position in MannKind during the fourth quarter worth about $69,000. Proficio Capital Partners LLC bought a new stake in MannKind in the 4th quarter valued at $70,000. Finally, Quantinno Capital Management LP acquired a new position in MannKind in the 3rd quarter valued at about $85,000.
Institutional investors own 49.55% of the company’s stock. Analyst Upgrades and Downgrades A number of equities research analysts have recently issued reports on MNKD shares.
Mizuho started coverage on shares of MannKind in a research report on Thursday. They issued an “outperform” rating and a $12.00 target price for the company.
Wells Fargo & Company assumed coverage on shares of MannKind in a report on Friday, December 20th. They issued an “overweight” rating and a $9.00 price objective for the company.
Wedbush reissued an “outperform” rating and set a $11.00 target price on shares of MannKind in a research note on Thursday, February 27th. Royal Bank of Canada upgraded shares of MannKind from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $7.
00 to $10.00 in a research report on Thursday, December 19th. Finally, StockNews.
com raised MannKind from a “hold” rating to a “buy” rating in a research report on Wednesday, March 19th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, MannKind has an average rating of “Buy” and a consensus target price of $9.
56. MannKind Stock Performance Shares of MNKD stock opened at $4.66 on Friday.
MannKind Co. has a 52 week low of $3.97 and a 52 week high of $7.
63. The firm’s 50-day simple moving average is $5.20 and its two-hundred day simple moving average is $6.
07. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of 66.
57 and a beta of 1.22. MannKind ( NASDAQ:MNKD – Get Free Report ) last posted its quarterly earnings results on Wednesday, February 26th.
The biopharmaceutical company reported $0.03 EPS for the quarter, hitting analysts’ consensus estimates of $0.03.
The firm had revenue of $76.78 million during the quarter, compared to analyst estimates of $74.99 million.
MannKind had a negative return on equity of 17.74% and a net margin of 8.07%.
Analysts forecast that MannKind Co. will post 0.1 earnings per share for the current year.
MannKind Company Profile ( Free Report ) MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Featured Articles Five stocks we like better than MannKind There Are Different Types of Stock To Invest In JPMorgan is a Buy, if You Can Handle The Volatility Bank Stocks – Best Bank Stocks to Invest In United States Steel’s Crash: An Unmissable Buying Opportunity What is the S&P/TSX Index? Rocket Lab Stock: Weathering the Storm, Time for a Comeback? Want to see what other hedge funds are holding MNKD? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for MannKind Co. ( NASDAQ:MNKD – Free Report ). Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.
com's FREE daily email newsletter ..
